3,4-dihydroxy-5-(methylsulfonyl)benzaldehyde | 116314-63-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dihydroxy-5-(methylsulfonyl)benzaldehyde
• 英文别名: 3,4-Dihydroxy-5-methanesulfonyl-benzaldehyde；3,4-dihydroxy-5-methylsulfonylbenzaldehyde
• CAS: 116314-63-7
• 化学式: C₈H₈O₅S
• 分子量: 216.215
• InChiKey: ZGQIMCQJGOORRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,2-二甲氧基-3-(甲硫基)苯 在 氰化钠 、 氢溴酸 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 22.0h， 生成 3,4-dihydroxy-5-(methylsulfonyl)benzaldehyde
  参考文献：
  名称：

  某些新型有效的选择性邻苯二酚O-甲基转移酶抑制剂的合成。

  摘要：

  合成了一系列二取代的邻苯二酚衍生物，并测试了其作为潜在的COMT抑制剂的能力。活性最高的化合物在体外的效价（IC50 = 3-6 nM）比已知的COMT抑制剂3'，4'-二羟基-2-甲基苯乙酮（U 0521，IC50 = 6000 nM）高出1000倍以上。新化合物也是高度选择性的COMT抑制剂，对儿茶酚胺的合成和代谢中涉及的其他必需酶没有活性。

  DOI：

  10.1021/jm00124a017

文献信息

• Pharmacologically active compounds, methods for the preparation thereof
  申请人：Orion-yhtyma Oy

  公开号：US04963590A1

  公开（公告）日：1990-10-16

  Pharmacologically active catechol derivatives of formula I ##STR1## wherein R.sub.1 and R.sub.2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R.sub.3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from ##STR2## wherein R.sub.4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R.sub.5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R.sub.4 and R.sub.5 together form a five to seven membered substituted cycloalkanone ring; --(CO).sub.n (CH.sub.2).sub.m --COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; ##STR3## wherein R.sub.8 and R.sub.9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; --NH--CO--R.sub.10 wherein R.sub.10 comprises a substituted alkyl group.

  公式I的药理活性儿茶酚衍生物，其中R.sub.1和R.sub.2独立地包括氢、烷基、酰基、可选择地取代的芳酰基、较低的烷基磺酰基或烷基氨基甲酰基，或者一起形成较低的烷基亚甲基或环烷基亚甲基，X包括电负取代基，如卤素、硝基、氰基、较低的烷基磺酰基、磺胺基、醛基、羧基或三氟甲基，R.sub.3包括氢、卤素、羟基烷基、氨基、硝基、氰基、三
• Small Molecule Xanthine Oxidase Inhibitors and Methods of Use
  申请人：BAYLOR COLLEGE OF MEDICINE

  公开号：US20140163045A1

  公开（公告）日：2014-06-12

  Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

  提供了小分子黄嘌呤氧化酶抑制剂，以及它们在治疗痛风或高尿酸血症中的使用方法。
• METHODS OF INHIBITING XANTHINE OXIDASE ACTIVITY IN A CELL
  申请人：Baylor College of Medicine

  公开号：US20140336204A1

  公开（公告）日：2014-11-13

  Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
• SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE
  申请人：Baylor College of Medicine

  公开号：US20140329909A1

  公开（公告）日：2014-11-06

  Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
• XANTHINE OXIDASE INHIBITORS AND METHODS OF USE
  申请人：Baylor College of Medicine

  公开号：US20150353471A1

  公开（公告）日：2015-12-10

  Small molecule xanthine oxidase inhibitors are provided, as well as compositions, methods for their use for treating disorders, mediated at least in part, by xanthine oxidase.